Targeting glioblastoma through tumor endothelial marker-1 (TEM-1)
George Coukos, MD, PhD
- Improved imaging and alternate therapies for GBM are direly needed.
- Investigators will develop a new generation of molecular agents for PET imaging based on targeting TEM-1, a cell-surface molecule present specifically on the GBM vasculature.
- Successful development of this vascular-specific PET imaging tool will markedly aid in the clinical diagnosis of primary or recurrent GBM and may address current limitations in brain imaging for monitoring response to treatment.